Elite Pharmaceuticals, Inc. (ELTP)
Stock Price Chart
Key Info
| Market Cap | 54.54M |
| Revenue (ttm) | 22.17M |
| Net Income (ttm) | -1.44M |
| Shares Out | 846.96M |
| EPS (ttm) | 0.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Oct 23, 2020 |
| Last Price | $0.0644 |
| Previous Close | $0.0660 |
| Change ($) | -0.0016 |
| Change (%) | -2.42% |
| Day's Open | 0.0615 |
| Day's Range | 0.0612 - 0.0657 |
| Day's Volume | 285,325 |
| 52-Week Range | 0.05 - 0.115 |
More Stats
| Market Cap | 54.54M |
| Enterprise Value | 56.79M |
| Earnings Date (est) | n/a |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 846.96M |
| Float | 598.18M |
| EPS (basic) | n/a |
| EPS (diluted) | 0.00 |
| FCF / Share | 0.00 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 757,074 |
| Short Ratio | 0.87 |
| Short % of Float | 0.13% |
| Beta | 1.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 2.46 |
| PB Ratio | 4.63 |
| Revenue | 22.17M |
| Operating Income | -307,103 |
| Net Income | -1.44M |
| Free Cash Flow | -1.17M |
| Net Cash | -2.24M |
| Net Cash / Share | 0.00 |
| Gross Margin | 35.98% |
| Operating Margin | -1.38% |
| Profit Margin | -6.50% |
| FCF Margin | -5.27% |
| ROA | -0.74% |
| ROE | -12.11% |
| ROIC | -16.20% |
Analyst Forecasts
Analyst Consensus: n/a
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.99 | 7.57 | 7.46 | 9.64 | 12.50 | 5.02 | 4.60 | 3.40 | 2.42 | 4.27 |
| Revenue Growth | 137.76% | 1.47% | -22.61% | -22.89% | 149.21% | 8.99% | 35.19% | 40.4% | -43.18% | - |
| Gross Profit | 7.98 | 2.87 | 3.95 | 3.74 | 8.01 | 2.00 | 1.37 | 1.09 | 1.41 | 1.59 |
| Operating Income | -2.29 | -9.16 | -9.05 | -7.36 | -8.32 | -16.51 | -5.28 | -1.56 | -1.97 | -0.89 |
| Net Income | -2.24 | -9.28 | -3.67 | 3.81 | -0.68 | 5.22 | -41.26 | 1.49 | -15.06 | -13.58 |
| Shares Outstanding | 832 | 814 | 796 | 839 | 674 | 591 | 463 | 349 | 259 | 100 |
| Earnings Per Share | - | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | -0.21 | - | -0.06 | -0.14 |
| Operating Cash Flow | -1.79 | -6.79 | -4.81 | -7.88 | -2.77 | -15.10 | -4.22 | -1.69 | -0.39 | 1.55 |
| Capital Expenditures | -0.03 | -0.02 | -0.27 | -1.10 | -1.95 | -2.00 | -0.50 | -0.15 | -0.62 | -0.49 |
| Free Cash Flow | -1.83 | -6.81 | -5.08 | -8.99 | -4.71 | -17.10 | -4.72 | -1.85 | -1.02 | 1.06 |
| Cash & Equivalents | 1.13 | 2.28 | 7.18 | 10.59 | 11.51 | 7.85 | 7.21 | 0.64 | 0.95 | 2.12 |
| Total Debt | 4.03 | 3.98 | 3.99 | 2.65 | 3.44 | 3.12 | 3.93 | 3.99 | 0.01 | 0.01 |
| Net Cash / Debt | -2.90 | -1.70 | 3.19 | 7.95 | 8.07 | 4.73 | 3.27 | -3.35 | 0.94 | 2.10 |
| Assets | 24.96 | 24.40 | 30.88 | 34.31 | 31.67 | 25.92 | 24.32 | 11.13 | 10.31 | 11.79 |
| Liabilities | 14.30 | 13.01 | 12.41 | 8.65 | 20.51 | 25.65 | 106 | 19.80 | 25.30 | 29.66 |
| Book Value | 10.66 | -2.51 | 4.57 | 25.66 | -33.12 | -34.73 | -81.20 | -8.67 | -14.98 | -17.87 |
Company Profile
Company Details
| Full Name | Elite Pharmaceuticals, Inc. |
| Country | United States |
| Employees | 43 |
| CEO | Nasrat A. Hakim |
Stock Information
| Ticker Symbol | ELTP |
| Stock Exchange | US OTC |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Unique Identifier | OTCMKTS: ELTP |
| IPO Date | July 23, 1998 |
Description
Elite Pharmaceuticals engages in the research, development, manufacture, and licensing of proprietary orally administered controlled-release drug delivery systems and products. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Hydromorphone HCl 8mg tablets for pains under the Dilaudid brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone brand; Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Methadone HCl tablets for pains under the Dolophine brand; and Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets for central nervous system diseases under the Adderall brand, as well as Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; and SequestOX, an immediate release Oxycodone with Naltrexone. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. It has a manufacturing and license agreement with Epic Pharma LLC; development and license agreement with SunGen Pharma, LLC; and strategic marketing alliance with Glenmark Pharmaceuticals, Inc. USA, as well as Lannett Company. Inc. The company was founded in 1984 and is headquartered in Northvale, New Jersey.